We have just finished our second round of medicinal chemistry, for optimisation of our marine-derived analgesic compound for the treatment of chronic pain.
This round of molecular profile optimisation has enabled the selection of our Lead drug, from over 120 analogue candidates. This is an important milestone in our technology.
A world-class biotechnology company in marine pharmaceutical research and development that aims to discover treatments to respond to unmet clinical needs.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
